Latest Health News

Lark Distilling Co. has reported its sixth consecutive quarter of sales growth, with net sales rising 11% to $5 million in Q2 FY26, as it prepares to launch a refreshed brand portfolio domestically and internationally.

Nico Resources has progressed key development activities at its Wingellina nickel-cobalt project, preparing for an infill drilling campaign as nickel and cobalt prices rally on Indonesian supply policy shifts.

ImpediMed reported a solid Q2 FY26 with $3.9 million in revenue and significant reimbursement gains for its lymphoedema technology, while launching new US Heart Health and Wellness initiatives.

Vitrafy Life Sciences has marked significant progress in Q2 FY2026 with a strategic partnership, commercial launch in North America, and advancing clinical trials, underpinning its growth in cryopreservation technology.

Mandrake Resources advances its Utah Lithium Project with a significant 3.3Mt lithium carbonate equivalent inferred resource, alongside key agreements for lithium offtake and uranium recovery.

Melbana Energy’s Q4 2025 report reveals a complex quarter with drilling setbacks in Cuba due to partner payment issues, alongside significant resource upgrades offshore Australia.

Adslot Ltd reported steady trading for Q2 FY26, highlighting progress in its StoreFront platform roll-out and a promising new partnership with Infomo. The company also posted positive cash flow and significant cost savings.

E79 Gold Mines Limited reported a solid quarter with a $3.1 million equity raise, ending December 2025 with $3.58 million in cash despite ongoing operating losses.

Sheffield Resources announces the novation of a secured loan facility to a Yansteel-related party, maintaining existing terms while progressing debt restructure negotiations for Kimberley Mineral Sands.

Powerhouse Ventures reports its inaugural operating cash flow positive quarter alongside strong fund performance and strategic fund launches, signalling a turning point for the investment house.

Atomo Diagnostics reported a robust 121% quarter-on-quarter revenue increase to $1.5 million, driven by new orders for its FebriDx Pascal and HIV Self-Test products. The company also secured a global licensing deal for a novel liver function test and expanded manufacturing capacity to support growing demand.

Patrys Limited has completed its acquisition of Reliis Pty Ltd, adding a promising injectable quetiapine program to its clinical pipeline and strengthening its board with two new directors.